Read More Pharma Industry News AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01… byPallavi MadhirajuSeptember 9, 2024